InvestorsHub Logo
Followers 37
Posts 1743
Boards Moderated 1
Alias Born 05/27/2010

Re: ospreyeye post# 19728

Sunday, 03/23/2014 9:10:09 AM

Sunday, March 23, 2014 9:10:09 AM

Post# of 42897
MCET WOONSOCKET, R.I., Jan. 15, 2014 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) has filed a U.S. provisional patent application concerning composition of matter, biological targets, mechanism of action, methods and formulations to achieve targeted tumor cell death.

Why this is important... Even though it's old? Well I did some digging into their 98 Page Annual report...

Fast Track Designation. The FDA’s fast track program is intended to facilitate the development and to expedite the review of drugs that are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the fast track program, the sponsor of a new drug candidate may request the FDA to designate the drug candidate for a specific indication as a fast track drug concurrent with or after the filing of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for fast track designation within 60 days of receipt of the sponsor’s request.

When appropriate, we and our collaborators intend to seek fast track designation or accelerated approval for our drug candidates. We cannot predict whether any of our drug candidates will obtain a fast track or accelerated approval designation, or the ultimate impact, if any, of the fast track or the accelerated approval process on the timing or likelihood of FDA approval of any of our drug candidates.


Multi-Cell owns patents 6,872,389 and 6,129,911... Gotta go lookup the pending ones.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.